Head-to-head comparison of 64Cu-DOTATATE and 68Ga -DOTATOC PET/CT: a prospective study of 59 patients with neuroendocrine tumors

Research output: Contribution to journalJournal article – Annual report year: 2016Researchpeer-review

Documents

DOI

  • Author: Johnbeck, C.B.

    University of Copenhagen, Denmark

  • Author: Knigge, U.

    University of Copenhagen, Denmark

  • Author: Loft, A.

    University of Copenhagen, Denmark

  • Author: Bertelsen, A.K.

    University of Copenhagen, Denmark

  • Author: Mortensen, J.

    University of Copenhagen, Denmark

  • Author: Oturai, P.

    University of Copenhagen, Denmark

  • Author: Langer, S.

    University of Copenhagen, Denmark

  • Author: Elema, Dennis Ringkjøbing

    The Hevesy Laboratory, Center for Nuclear Technologies, Technical University of Denmark, Frederiksborgvej 399, 4000, Roskilde, Denmark

  • Author: Kjaer, A.

    Righospitalet , Denmark

View graph of relations

Somatostatin receptor imaging is a valuable tool in the diagnosis, follow-up and treatment planning of neuroendocrine tumor (NET) patients. Positron emission tomography (PET) based tracers using 68Ga as the radioisotope have in most centers replaced single-photon emission tomography (SPECT) based tracers as the gold standard. 64Cu-DOTATATE is a new PET tracer that has been shown to be far superior compared to the SPECT tracer 111In-DTPA-octreotide. Due to advantages of 64Cu compared to 68Ga, we hypothesize that the tracer could have a higher sensitivity than 68Ga-based tracers. To test this hypothesis, we compared on a head-to-head basis the diagnostic performance of 64Cu-DOTATATE with that of 68Ga -DOTATOC in NET patients.

Objectives 64Cu-DOTATATE is a new PET tracer for somatostatin receptor imaging. 64Cu-DOTATATE may potentially have a higher sensitivity than the current gold standards, due to advantages of 64Cu compared to 68Ga. The aim was to test this hypothesis on a head to head basis in neuroendocrine tumor patients (NET).

Methods Fifty-nine NET patients were scanned with 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT and discordant lesions were verified through follow-up. Both scans were made within a week (1-5 days apart).

Results A total of 701 lesions were concordantly detected on both 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT scans while additional 68 lesions were found by only one of the two scans. 64Cu-DOTATATE showed 42 discordant lesions of which 33 were found to be true positive on follow up. 68Ga-DOTATOC showed 26 discordant lesions, but only 7 were found to be true positive on follow up. False positives were mainly lymph node lesions. Eighty-three percent of the additional true positive lesions were found by 64Cu-DOTATATE. 64Cu-DOTATATE and 68Ga-DOTATOC discovered additional true lesions in 13 and 3 patients, respectively. All patients with additional lesions also had concordant lesions found by both scans.

Conclusions Although patient based sensitivity was the same for 64Cu-DOTATATE and 68Ga-DOTATOC in this cohort, more lesions were found by 64Cu-DOTATATE. Furthermore the shelve life of more than 24 hours and a scan window of at least 3 hours make 64Cu-DOTATATE logistically attractive to use in the clinic.



Original languageEnglish
JournalThe Journal of Nuclear Medicine
Volume58
Issue number3
Pages (from-to)451-457
ISSN0161-5505
DOIs
Publication statusPublished - 2016
CitationsWeb of Science® Times Cited: No match on DOI

    Research areas

  • 64Cu-DOTATATE, 68Ga-DOTATOC, Neuroendocrine, Oncology, Endocrine, PET/CT, Neuroendocrine tumors, Somatostatin receptor imaging

Download statistics

No data available

ID: 127312776